The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 10, 2022

Filed:

Apr. 18, 2018
Applicants:

Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);

Technische Universität München, Munich, DE;

Inventors:

Laura Sepp-Lorenzino, Cambridge, MA (US);

Ulrike Protzer, Munich, DE;

Thomas Michler, Munich, DE;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/713 (2006.01); A61K 31/7088 (2006.01); A61K 39/12 (2006.01); A61K 39/29 (2006.01); A61K 47/54 (2017.01); A61P 31/20 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/292 (2013.01); A61K 31/713 (2013.01); A61K 47/549 (2017.08); A61P 31/20 (2018.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01);
Abstract

The present invention provides methods for the treatment of a subject having a Hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, using a combination of an RNAi agent that targets HBV and an HBV vaccine. It is disclosed a RNAi agent and an HBV vaccine for use in treatment of HBV infection, comprising sequentially administering to the subject having an HBV infection: a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent forms a double stranded region; b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, and a first HBV surface antigen (HBsAg) polypeptide; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, and/or a second HBsAg polypeptide, wherein the second HBcAg polypeptide, and/or the second HBsAg polypeptide, shares at least one epitope with at least one of the first HBcAg polypeptide, and/or the first HBsAg polypeptide.


Find Patent Forward Citations

Loading…